WHO Lists First Bundibugyo Ebola Test For Emergency Use

The World Health Organization (WHO) has granted Emergency Use Listing to the first molecular diagnostic test for the Bundibugyo Ebola virus. This listing is a milestone for international public health, as it provides a rapid, verified tool to detect the virus during outbreaks. This development occurs alongside the initiation of a treatment trial in the Democratic Republic of Congo (DRC) for the same strain.

Clinical researchers in the DRC are currently evaluating a dual approach to treating the Bundibugyo Ebola virus. The trial involves testing the experimental MBP134 antibody, developed by Mapp Biopharmaceutical, as a standalone treatment or in combination with Gilead Sciences’ antiviral drug remdesivir. These parallel efforts to improve testing speed and treatment efficacy are critical to limiting the mortality rate in endemic regions.

For the international health community, the speed at which these tools are being brought to market is significant. While Ebola outbreaks are localized, the ability to deploy rapid, reliable diagnostics and effective therapies is a cornerstone of global pandemic preparedness. These developments reinforce the importance of global medical collaboration and the rigorous vetting of diagnostics to contain rare but lethal viruses before they cause widespread international crises.